CDK6 and hepatocellular carcinoma: Upon analysis, we observed a significant upregulation of CDK6 in lenvatinib-resistant HCC patients when compared with sensitive group, further verifying the role of CDK6 in driving lenvatinib resistance in HCC (Fig. 1j).